| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 04/02/2002 | US6365598 Pyrroloquinolines for treatment of obesity |
| 04/02/2002 | US6365402 Growth differentiation factor-9 |
| 04/02/2002 | US6365389 Human protein kinase H2LAU20 |
| 04/02/2002 | US6365370 Dna which codes for 5-hydroxytryptamine 3-c protein of defined amino acid sequence; antiinflammatory agents; treatment of huntington's disease, alzheimer's disease and others |
| 04/02/2002 | US6365164 Injecting therapeutic amount of botulinum toxin into prostate gland of patient, thereby alleviating symptoms of prostatic hyperplasia, benign prostatic hyperplasia or prostatic enlargement |
| 04/02/2002 | US6365159 Spo-rel |
| 04/02/2002 | CA2144047C Method and compositions for maintaining glomerular filtration rate while inhibiting extracellular matrix accumulation |
| 03/28/2002 | WO2002024924A2 Protein phosphatases |
| 03/28/2002 | WO2002024923A1 Polypeptide having phospholipase a2 actiivty |
| 03/28/2002 | WO2002024910A2 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof |
| 03/28/2002 | WO2002024909A2 Receptor nucleic acids and polypeptides |
| 03/28/2002 | WO2002024891A2 B7-like molecules and uses thereof |
| 03/28/2002 | WO2002024702A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | WO2002024698A1 Xanthine phosphodiesterase v inhibitors |
| 03/28/2002 | WO2002024697A1 Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
| 03/28/2002 | WO2002024683A1 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives |
| 03/28/2002 | WO2002024672A2 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 03/28/2002 | WO2002024653A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | WO2002024647A1 Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| 03/28/2002 | WO2002024639A1 Cyclopentane derivatives as therapeutic agents |
| 03/28/2002 | WO2002024635A2 Aminoalcohol derivatives |
| 03/28/2002 | WO2002024629A1 Zwitterionic tachykinin receptor antagonists |
| 03/28/2002 | WO2002024221A2 Notch receptor agonists and uses |
| 03/28/2002 | WO2002024209A1 Fluid for haemofiltration |
| 03/28/2002 | WO2002016554A9 Probiotics products containing lactic acid bacterium |
| 03/28/2002 | WO2001097751A3 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 03/28/2002 | WO2001090106A3 Tryasolyl tropane derivatives as ccr5 modulators |
| 03/28/2002 | WO2001089454A3 Proteus mirabilis-based vaccine |
| 03/28/2002 | WO2001085762B1 Cancer diagnosis and assays for screening anti-cancer agents |
| 03/28/2002 | WO2001070977A3 Fibroblast growth factor receptor-like molecules and uses thereof |
| 03/28/2002 | WO2001064631A3 Derives de polyfluoroalkylimidazole et leur utilisation en tant qu'antagonistes des recepteur muscariniques m3 et serotoniques 5-ht4 |
| 03/28/2002 | WO2001038486A3 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | WO2001035936A3 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases |
| 03/28/2002 | WO2001032216A3 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 03/28/2002 | WO2000066102A3 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| 03/28/2002 | WO2000063241A9 Methods and compositions for modulating an immune response |
| 03/28/2002 | US20020038150 Injectable implants for tissue augmentation and restoration |
| 03/28/2002 | US20020038030 For therapy of inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's |
| 03/28/2002 | US20020037915 4-(4-(1- phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5-methylthiothiophene-2 -carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases |
| 03/28/2002 | US20020037895 Wherein the lactone ring is modified; preventing or treating disorders or diseases mediated by LFA-1 (Leukocyte Function-associated Antigen-1) ICAM-1 (intercellular adhesion molecules) interactions; autoimmune disorders, inflammation |
| 03/28/2002 | US20020037878 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/28/2002 | US20020037852 Anticarcinogenic agents |
| 03/28/2002 | US20020037850 Genetic engineering; binding to antibodies |
| 03/28/2002 | US20020037841 Blood disorders; drug in aqueous solution |
| 03/28/2002 | US20020037549 ABC transport polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | US20020037524 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer, inflammation, autoimmune disease and infections |
| 03/28/2002 | US20020037523 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of nervous system, autoimmune, inflammation, glomerulonephritis and osteoporosis disorders |
| 03/28/2002 | US20020037332 Licorice extract for use as a medicament |
| 03/28/2002 | US20020037329 Biochemically balanced peritoneal dialysis solutions |
| 03/28/2002 | DE10043321A1 Transdermales therapeutisches System Transdermal therapeutic system |
| 03/28/2002 | CA2433157A1 Cyclopentane derivatives as therapeutic agents |
| 03/28/2002 | CA2423356A1 Zwitterionic tachykinin receptor antagonists |
| 03/28/2002 | CA2423106A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | CA2423104A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/28/2002 | CA2423071A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | CA2423058A1 Polypeptide having phospholipase a2 activity |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2420862A1 Protein phosphatases |
| 03/28/2002 | CA2416136A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 03/27/2002 | EP1191026A1 New pyridazine endothelin antagonists |
| 03/27/2002 | EP1190717A2 Licorice extract for use as a medicament |
| 03/27/2002 | EP1190059A1 Sgip peptides |
| 03/27/2002 | EP1190051A2 Human transport proteins |
| 03/27/2002 | EP1189942A1 Somatostatin agonists |
| 03/27/2002 | EP1189941A1 Neuromedin b and somatostatin receptor agonists |
| 03/27/2002 | EP1189888A1 HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS |
| 03/27/2002 | EP1189609A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| 03/27/2002 | EP1189598A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 03/27/2002 | EP0946503B1 Nitromethylthiobenzene derivatives as inhibitors of aldose reductase |
| 03/27/2002 | EP0873336B1 Antagonists of gonadotropin releasing hormone |
| 03/27/2002 | EP0734255B1 Novel potassium channel agonist produced from trichoderma virens |
| 03/27/2002 | CN1342202A Soluble receptor BR43X2 and methods for using them for therapy |
| 03/27/2002 | CN1342166A GLP-1 analogues |
| 03/27/2002 | CN1342163A Ketolide antibiotics |
| 03/27/2002 | CN1342157A Substituted pyrazoles ASP38 kinase inhibitors |
| 03/27/2002 | CN1342153A Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in production of medicaments |
| 03/27/2002 | CN1342077A Inhibition of formation of vascular hyperpermeability |
| 03/27/2002 | CN1342073A Antioxidant compositions and methods for companion animals |
| 03/27/2002 | CN1341427A Chinese medicine for curing prostatosis |
| 03/27/2002 | CN1081460C Use of medicine for reducing tissue damage associated with non-cardiac ischemia by aldose reductase inhibitor |
| 03/26/2002 | US6362371 β2- adrenergic receptor agonists |
| 03/26/2002 | US6362237 Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| 03/26/2002 | US6362190 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, n'-((1-(aminoiminomethyl)4-piperidinyl) methyl)-n-(3,3-diphenylpropionyl)-l-proline amide |
| 03/26/2002 | US6362182 Hypotensive agents; anticholesterol agents; benign prostatic hypertropic |
| 03/26/2002 | US6362178 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| 03/26/2002 | US6361778 Carboxyl terminal of papillomavirus L1 region is not required for formation of virus-like particles |
| 03/26/2002 | CA2032498C Novel 8-substituted-2-aminotetralines |
| 03/21/2002 | WO2002022647A1 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022599A2 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | WO2002022585A1 Tetrahydroquinoline compounds |
| 03/21/2002 | WO2002022574A1 Tricyclic heterocyclic compound, process for producing the same, and use thereof |
| 03/21/2002 | WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | WO2002022572A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022170A1 Insulin secretion controlling agents |
| 03/21/2002 | WO2002022163A1 Remedies for ischemic diseases |